Alexion Pharmaceuticals Inc (ALXN)-Financial and Strategic SWOT Analysis Review

Alexion Pharmaceuticals Inc (ALXN)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH66520FSA
  • |
  • Pages: 60
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Alexion Pharmaceuticals Inc (ALXN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alexion Pharmaceuticals Inc (Alexion) focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic diseases, cancer, neurological, and autoimmune disorders. The company's marketed product portfolio includes Soliris (eculizumab) used for two indications paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS); Strensiq (asfotase alfa) for the treatment of hypophosphatasia (HPP)and Kanuma (sebelipase alfa) for the treatment of Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D). The company's research and development focuses on developing its lead product Soliris, for various other serious disease states. It also has other candidates in development targeting rare metabolic and inflammatory disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc Key Recent Developments

Apr 27,2017: Alexion Reports First Quarter 2017 Results

Mar 27,2017: Alexion Appoints Ludwig Hantson, Ph.D., As Chief Executive Officer

Mar 02,2017: Leonard Bell, M.D., Alexion's Founder, Announces Plans to Retire as Chairman and Board Member

Feb 16,2017: Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017

Jan 04,2017: Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Alexion Pharmaceuticals Inc-Key Facts 6

Alexion Pharmaceuticals Inc-Key Employees 7

Alexion Pharmaceuticals Inc-Key Employee Biographies 8

Alexion Pharmaceuticals Inc-Major Products and Services 9

Alexion Pharmaceuticals Inc-Pharmaceutical Pipeline Products Data 10

Alexion Pharmaceuticals Inc, Pipeline Products by Therapy Area 10

Alexion Pharmaceuticals Inc, Pipeline Products by Development Phase 11

Alexion Pharmaceuticals Inc-History 12

Alexion Pharmaceuticals Inc-Company Statement 16

Alexion Pharmaceuticals Inc-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Section 2-Company Analysis 21

Alexion Pharmaceuticals Inc-Business Description 21

Alexion Pharmaceuticals Inc-Corporate Strategy 22

Alexion Pharmaceuticals Inc-SWOT Analysis 23

SWOT Analysis-Overview 23

Alexion Pharmaceuticals Inc-Strengths 23

Alexion Pharmaceuticals Inc-Weaknesses 24

Alexion Pharmaceuticals Inc-Opportunities 25

Alexion Pharmaceuticals Inc-Threats 26

Alexion Pharmaceuticals Inc-Key Competitors 27

Section 3-Company Financial Ratios 28

Financial Ratios-Capital Market Ratios 28

Financial Ratios-Annual Ratios 29

Performance Chart 32

Financial Performance 32

Financial Ratios-Interim Ratios 33

Financial Ratios-Ratio Charts 34

Section 4-Company's Lifesciences Financial Deals and Alliances 35

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 35

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 36

Alexion Pharmaceuticals Inc, Recent Deals Summary 37

Section 5-Company's Recent Developments 38

Apr 27, 2017: Alexion Reports First Quarter 2017 Results 38

Mar 27, 2017: Alexion Appoints Ludwig Hantson, Ph.D., As Chief Executive Officer 40

Mar 02, 2017: Leonard Bell, M.D., Alexion's Founder, Announces Plans to Retire as Chairman and Board Member 41

Feb 16, 2017: Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017 42

Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 44

Dec 12, 2016: Alexion Pharmaceuticals appoints interim CEO 46

Dec 12, 2016: Alexion's Board Of Directors Announces New Leadership Appointments 48

Oct 27, 2016: Alexion Reports Third Quarter 2016 Results 50

Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 52

Jul 28, 2016: Alexion Reports Second Quarter 2016 Results 54

Section 6-Appendix 56

Methodology 56

Ratio Definitions 56

About GlobalData 60

Contact Us 60

Disclaimer 60

List of Figures

Alexion Pharmaceuticals Inc, Pipeline Products by Therapy Area 10

Alexion Pharmaceuticals Inc, Pipeline Products by Development Phase 11

Alexion Pharmaceuticals Inc, Performance Chart (2012-2016) 32

Alexion Pharmaceuticals Inc, Ratio Charts 34

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 35

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 36

List of Tables

Alexion Pharmaceuticals Inc, Key Facts 6

Alexion Pharmaceuticals Inc, Key Employees 7

Alexion Pharmaceuticals Inc, Key Employee Biographies 8

Alexion Pharmaceuticals Inc, Major Products and Services 9

Alexion Pharmaceuticals Inc, Number of Pipeline Products by Therapy Area 10

Alexion Pharmaceuticals Inc, Number of Pipeline Products by Development Stage 11

Alexion Pharmaceuticals Inc, History 12

Alexion Pharmaceuticals Inc, Subsidiaries 18

Alexion Pharmaceuticals Inc, Key Competitors 27

Alexion Pharmaceuticals Inc, Ratios based on current share price 28

Alexion Pharmaceuticals Inc, Annual Ratios 29

Alexion Pharmaceuticals Inc, Annual Ratios (Cont...1) 30

Alexion Pharmaceuticals Inc, Annual Ratios (Cont...2) 31

Alexion Pharmaceuticals Inc, Interim Ratios 33

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 35

Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 36

Alexion Pharmaceuticals Inc, Recent Deals Summary 37

Currency Codes 56

Capital Market Ratios 56

Equity Ratios 57

Profitability Ratios 57

Cost Ratios 58

Liquidity Ratios 58

Leverage Ratios 59

Efficiency Ratios 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alexion Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8599
Site License
USD 250 INR 17198
Corporate User License
USD 375 INR 25796

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com